Minnesota is currently home to 2090 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT05720039
Recruiting
This study evaluates the safety and effectiveness of the da Vinci SP Surgical System compared to Open NSM in Nipple Sparing Mastectomy procedures.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/22/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Register for Updates
MRI-Guided Cryoablation for Focal Native Prostate Cancer
NCT04797039
Recruiting
The purpose of this research is to collect data about the MRI cryoablation procedure your doctor(s) would normally perform in order to treat the participants focal prostate cancer and to evaluate the participants condition after the participants treatment is performed. Participants have been asked to take part in this research because the participants have been diagnosed with prostate cancer and scheduled to have an ablation procedure.
Gender:
MALE
Ages:
Between 30 years and 100 years
Trial Updated:
04/22/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Malignant Neoplasm of Prostate (Diagnosis)
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: University of Minnesota Blood and Marrow Transplant Program - Pediatrics, Minneapolis, Minnesota
Conditions: SCID
Register for Updates
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
NCT03313011
Recruiting
The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Apraxia of Speech, Non-fluent Aphasia, Primary Progressive Aphasia, Primary Progressive Nonfluent Aphasia
Register for Updates
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
NCT06065436
Recruiting
The purpose of this research is to determine whether or not low-intensity shockwave therapy (LiSWT) with Xiaflex treatment will result in greater improvements to the curvature of the penis.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Peyronie Disease, Erectile Dysfunction
Register for Updates
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis... Read More
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/21/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Prostate Cancer
Register for Updates
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368
Recruiting
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy. The study will recruit patients with a confirmed diagnosis of HES and who are on stable HES therapy for at least 4 weeks prior to randomization (Visit 2). Eligible participants must have uncontrolled HES with a history of repeated flare (≥2 flares in the previous 12 months) and blood eosinophil count of ≥1,000... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: GSK Investigational Site, Rochester, Minnesota
Conditions: Hypereosinophilic Syndrome
Register for Updates
DALY II USA/ MB-CART2019.1 for DLBCL
NCT04792489
Recruiting
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation
Register for Updates
Is Our Microbiome a Predictor of Cardiac Risk
NCT02013284
Recruiting
The purpose of this study is to determine a relationship between a person's flora/bacteria in their gut (the intestinal microbiome) and their risk of cardiovascular disease. Investigators will look at inflammatory markers in the blood and also look at the genome of the bacteria in the gut.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Coronary Artery Disease
Register for Updates
Oral and Intravenous Methadone for Analgesia in Cardiac Surgery
NCT06720415
Recruiting
The purpose of this study is to compare the effects of administration of oral methadone preoperatively and intravenous methadone upon induction of general anesthesia on postoperative pain for patients undergoing elective cardiac surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Anesthesia, Cardiac Surgery
Register for Updates
Microelectrode Recordings From the Vagus Nerve in Awake Humans
NCT06016686
Recruiting
This Anchillary project uses a refined technique of ultrasound-guided microneurography of the human cervical vagus nerve, an approach developed by Professor Vaughan Macefield and used safely to-date in 44 prior study participants. The overall goal of this project is to build upon prior data obtained using this approach by undertaking a detailed neurophysiological investigation of the human vagus nerve and to identify the nerve fibers activated during vagal nerve stimulation (VNS) in participant... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/20/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Epilepsy
Register for Updates
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
NCT05180773
Recruiting
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/19/2025
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Peripartum Cardiomyopathy, Postpartum
Register for Updates